AnaptysBio Inc To virtual BTLA Agonist (ANB032) R&D Event Transcript
Good day, and thank you for standing by. Welcome to the BTLA Agonist R&D event. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Dan Faga, Interim CEO of AnaptysBio.
Good afternoon, and welcome to AnaptysBio's R&D event focused on ANB032, our BTLA agonist. Today's presentation contains statements about our current plans that are forward-looking.
Joining me from Anaptys are Dr. Paul Lizzul, our Chief Medical Officer; and Dr. Martin Dahl, our SVP of Research. We're going to cover a significant amount of exciting new data and information, followed by Q&A. This will include an overview of checkpoint agonists, including deeper insight into ANB032's mechanism of action targeting BTLA.
We'll present translational preclinical data supporting the rationale to pursue development of a BTLA agonist to treat atopic dermatitis. And we will also review our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |